ArticleObesity (Silver Spring, Md.)2025
Semaglutide-induced weight loss improves mitochondrial energy efficiency in skeletal muscle.
Article in Obesity (Silver Spring, Md.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Review
- Semaglutide Attenuates Inflammatory Macrophage Polarization and Promotes Changes Associated with Mitochondrial Biogenesis Through cAMP-Dependent Signaling.Biomedicines · 2026Article
- Article
- Beyond Weight Loss: Skeletal Muscle Health During Incretin-Based Therapy in Patients with Diabesity.Nutrients · 2026Review
- Semaglutide-induced loss of skeletal muscle mass is blunted by co-administration of ketone esters.JCI insight · 2026Article
- Negative effects of semaglutide on bone in obese mice.Cell reports. Medicine · 2026Article
- Incretin-Based Therapies in Sports: Pharmacological Mechanisms, Performance-Enhancing Potential, and Anti-Doping Implications-A Narrative Review.International journal of molecular sciences · 2026Review
- 15-PGDH inhibition promotes muscle repair and strength recovery during GLP-1 receptor agonist-induced weight loss.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Met@MPDA rejuvenates BMSC energy metabolism to promote bone regeneration in semaglutide-treated obese periodontitis.Materials today. Bio · 2026Article
- Weight loss with GLP-1 medicines does not result in a disproportionate loss of muscle mass or function in obese mice and humans.Cell reports. Medicine · 2026Article
- Females are protected from semaglutide-induced muscle loss inbioRxiv : the preprint server for biology · 2026Article
- 15-PGDH Inhibition Overcomes Muscle Regenerative Deficit Seen With GLP1-Receptor Agonist-Induced Weight Loss.bioRxiv : the preprint server for biology · 2026Article
- Muscle health in the modern era of incretin-based therapies.European journal of clinical investigation · 2026Review
- Mitochondrial Dysfunction in MASLD: Evidence in Dietary Models and Potential Therapeutic Interventions.Biochemistry research international · 2026Review
- Impact of Semaglutide on fat mass, lean mass and muscle function in patients with obesity: The SEMALEAN study.Diabetes, obesity & metabolism · 2026Article
- Semaglutide Exacerbates Stunting in Growth-Impaired Juvenile Male Mice via Reduced Energy Metabolism.Journal of the Endocrine Society · 2025Article
- Impact of Incretin-Based Therapy on Skeletal Muscle Health.Medicina (Kaunas, Lithuania) · 2025Review
- Semaglutide-induced weight loss improves mitochondrial energy efficiency in skeletal muscle.Obesity (Silver Spring, Md.) · 2025Article
- GLP-1 agonists and exercise: the future of lifestyle prioritization.Frontiers in clinical diabetes and healthcare · 2025Review
Corrections and comments
- Update of
Authors and funding
10 authors.
Funding
Abstract
objectiveGlucagon-like peptide-1 receptor agonists (e.g., semaglutide) potently induce weight loss, thereby reducing obesity-related complications. However, weight regain occurs when treatment is discontinued. An increase in skeletal muscle oxidative phosphorylation (OXPHOS) efficiency upon diet-mediated weight loss has been described, which may contribute to reduced systemic energy expenditure and weight regain. We set out to determine the unknown effect of semaglutide on muscle OXPHOS efficiency.
methodsC57BL/6J mice were fed a high-fat diet for 12 weeks before receiving semaglutide or vehicle for 1 or 3 weeks. The rates of ATP production and oxygen (O
resultsSemaglutide treatment led to significant reductions in fat and lean mass. Semaglutide improved skeletal muscle OXPHOS efficiency, measured as ATP produced per O
conclusionsThese data indicate that weight loss with semaglutide treatment increases skeletal muscle mitochondrial efficiency. Future studies could test whether it contributes to weight regain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.